Purines (including Hydrogenated) (e.g., Adenine, Guanine, Etc.) Patents (Class 514/45)
-
Publication number: 20130274220Abstract: The present invention discloses methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5?-methylthioinosine phosphorylase (MTIP) inhibitor, as well as assays for identifying such inhibitors, and compounds and pharmaceutical compositions comprising the inhibitors.Type: ApplicationFiled: November 28, 2011Publication date: October 17, 2013Applicants: Industrial Research Limited, Albert Einstein College of Medicine of Yeshiva UniversityInventors: Vern L. Schramm, Keith Clinch, Peter Charles Tyler, Gary Brian Evans, Richard Hubert Furneaux
-
Patent number: 8557790Abstract: The present disclosure provides the use of an A3R agonist, such as IB-MECA, for reducing in a subject, preferably, human subject, intra ocular pressure (IOP). Similarly, the invention provides a pharmaceutical composition and a method for reducing IOP in a subject making use of the A3R agonist.Type: GrantFiled: May 16, 2010Date of Patent: October 15, 2013Assignee: Can-Fite Biopharma Ltd.Inventors: Pnina Fishman, Mordechai Farbstein
-
Publication number: 20130261073Abstract: The present invention provides a novel compound capable of inhibiting cardiac adenylyl cyclase. The present invention relates to a compound represented by the following formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof: where R1, R2 and R3 each independently represent a hydrogen atom or an acyl group having an acidic or basic substituent, provided that all of R1, R2 and R3 are not simultaneously a hydrogen atom. The present invention also provides a modulator of adenylyl cyclase activity, a pharmaceutical composition and a food composition, all of which comprise the above-described compound or a pharmaceutically acceptable salt, ester or solvate thereof.Type: ApplicationFiled: October 20, 2011Publication date: October 3, 2013Applicants: National Univeristy Corporation Yokohama National University, Public University Corporation Yokohama City UniversityInventors: Yoshihiro Ishikawa, Satoshi Okumura, Yujiro Hoshino, Seiichi Inoue
-
Patent number: 8541391Abstract: The invention relates to novel crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-(?-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.Type: GrantFiled: October 27, 2011Date of Patent: September 24, 2013Assignee: ViroPharma IncorporatedInventors: Eugene C. Amparo, Cristina Stoica, Mihaela Pop, Jaroslaw Mazurek
-
Publication number: 20130244964Abstract: The present invention provides an isolated HIV-1 mutant and isolated nucleic acid molecules comprising HIV-RT coding sequences harboring a novel mutation in the S68 codon, and in particular, deletions of the S68 codon. This novel deletion reduces the sensitivity of HIV to various nucleoside reverse transcriptase inhibitors. Methods of using this mutation for selecting effective antiretroviral agents in vitro and in vivo, methods for monitoring infection progression in HIV-infected individuals and methods for avoiding the emergence of and/or to treat individuals infected with HIV comprising mutations, including deletions, at the S68 codon of HIV-RT are provided.Type: ApplicationFiled: November 9, 2012Publication date: September 19, 2013Applicant: EMORY UNIVERSITYInventor: Raymond F. Schinazi
-
Publication number: 20130244965Abstract: The invention is generally related to assays and methods for determining the risk of an HIV+ individual for developing a macrophage-mediated disease using measurement of soluble CD163 levels in a biological sample. The invention also provides assays and methods for monitoring efficacy of a treatment or a drug for a macrophage-mediated disease, and assays and methods for screening for agents to treat a macrophage-mediated disease in an HIV+ individual by monitoring soluble CD163 levels.Type: ApplicationFiled: September 27, 2011Publication date: September 19, 2013Applicants: THE GENERAL HOSPITAL CORPORATION, TRUSTEES OF BOSTON COLLEGEInventors: Kenneth C. Williams, Tricia Burdo, Steven K. Grinspoon, Eric Rosenberg
-
Publication number: 20130237491Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.Type: ApplicationFiled: April 12, 2013Publication date: September 12, 2013Applicant: Roche Palo Alto LLCInventors: Rene Robert Devos, Christopher John Hobbs, Wen-Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
-
Publication number: 20130224110Abstract: The present invention relates to a method of increasing blood brain barrier (“BBB”) permeability in a subject. This method involves administering to the subject an agent or agents which activate both of the A1 and A2A adenosine receptors. Also disclosed is a method to decrease BBB permeability in a subject. This method includes administering to the subject an agent which inhibits or blocks the A2A adenosine receptor signaling. Compositions relating to the same are also disclosed.Type: ApplicationFiled: September 16, 2011Publication date: August 29, 2013Applicant: CORNELL UNIVERSITYInventor: Margaret S. Bynoe
-
Patent number: 8513214Abstract: The invention provides for novel 2-Deoxyadenosine compounds, which can treat HIV infection at low cytotoxicity values. Substitution at the 4?-position provided compounds which demonstrated low cytotoxicity values in an ATP-based cytotoxicity assay.Type: GrantFiled: November 10, 2008Date of Patent: August 20, 2013Assignee: The United States of America as Represented by the Secretary of the Dept. of Health and Human ServicesInventors: Bao-Han C. Vu, Maqbool A. Siddiqui, Victor E. Marquez, Stephen H. Hughes, Paul L. Boyer
-
Patent number: 8513205Abstract: The present invention relates to compounds, in particular, dual antagonists comprising a nucleoside reverse transcriptase inhibitor (NRTI) or a nucleoside competitive reverse transcriptase inhibitor and a non-nucleoside reverse transcriptase inhibitor (NNRTI), linked together using a chemical linker, which may be used to inhibit HIV (HIV-1) reverse transcriptase and in the treatment of HIV infections, more severe cases of HIV infections, including ARC and AIDS, including reducing the likelihood of these infections and disease states.Type: GrantFiled: April 9, 2009Date of Patent: August 20, 2013Assignees: Yale University, University of Cape TownInventors: Karen S. Anderson, Roger Hunter
-
Publication number: 20130209550Abstract: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.Type: ApplicationFiled: July 28, 2011Publication date: August 15, 2013Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Brian Agnew, David Graham, Upinder Singh, Scott Grecian
-
Publication number: 20130203694Abstract: Rel proteins as a novel therapeutic agent for treating bacterial threats. More specifically, a novel class of compounds of Formula (I) as disclosed herein which possess anti-bacterial activity and which inhibit RelA, RelSeq or RelSpo synthetic activity or bacterial spore formation. Also, pharmaceutical compositions of such compounds and a method of combating bacteria, or treating bacterial infections, by administering to a subject in need thereof such compounds or pharmaceutical compositions.Type: ApplicationFiled: August 3, 2011Publication date: August 8, 2013Applicant: YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Ezequiel Wexselblatt, Joshua Katzhendler, Gad Glaser, Sigal Ben Yehuda, Roee Vidavski, Hafiz Mawasi, Ilana Kaspy, Yaara Oppenheimer-Shaanan
-
Publication number: 20130196940Abstract: The present invention provides novel anhydrous polymorph forms of 2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate (Compound A). The present invention also provides processes for preparation of the anhydrous polymorphic forms of compound A.Type: ApplicationFiled: January 25, 2013Publication date: August 1, 2013Applicant: INOTEK PHARMACEUTICALS CORPORATIONInventor: Inotek Pharmaceuticals Corporation
-
Publication number: 20130189246Abstract: Provided are compositions and methods for treatment of ophthalmic conditions, such as retinal detachment and age-related macular degeneration. Various fluorenone derivatives described herein can stimulate fluid removal from the subretinal space and down-regulate reactive gliosis. Administration of compounds described herein can provide an alternative or an adjunct to an invasive procedure to reattach the retina.Type: ApplicationFiled: November 5, 2010Publication date: July 25, 2013Applicant: The Trustees of Columbia University in the City of New YorkInventor: Konstantin Petrukhin
-
Publication number: 20130183277Abstract: Provided are compositions and methods for increasing patient CD4+ cell count while undergoing treatment for immune-mediated disease, cancer, heart disease, neurodegenerative disease, or infectious disease by administering to the patient a nutrient composition including, inter alia, alpha lipoic acid, acetyl L-carnitine, and N-acetyl-cysteine.Type: ApplicationFiled: December 19, 2012Publication date: July 18, 2013Inventor: Jon D. Kaiser
-
Publication number: 20130171145Abstract: Compounds and compositions useful for the treatment of liver diseases and methods of treating liver diseases are disclosed. The compounds of the invention specifically interact with heteromers of cannabinoid receptors as compared to monomers or homodimers. The invention also relates to methods of screening for compounds useful for the treatment of liver diseases and to methods of screening for diacylglycerol lipase inhibitors.Type: ApplicationFiled: January 25, 2011Publication date: July 4, 2013Applicant: MOUNT SINAI SCHOOL OF MEDICINEInventors: Lakshmi A. Devi, Raphael Rozenfeld
-
Publication number: 20130172286Abstract: This invention relates to a functional food supplement, specifically intended to supplement the enteral or oral nutrition of patients with neurological or neurodegenerative alterations, and for the prevention of cognitive or behaviour disorders, especially in the case of elderly persons, where the functional ingredient especially conceived for the nourishment of patients suffering from, or prone to neurological or neurodegenerative alterations, cognitive deterioration or behaviour disorders comprises a mixture of UMP (uridine monophosphate or uridine) and/or IMP (inosine monophosphate or inosine), vitamins of the B group (B1, B6, B9 and B7), phospholipids and gangliosides and sialic acid, as well as a large amount of DHA.Type: ApplicationFiled: March 31, 2010Publication date: July 4, 2013Applicant: VEGENAT, S.A.Inventors: Angel Gil Hernandez, Paloma San Roman Pais, Milagros Perez Rodriguez
-
Publication number: 20130171268Abstract: The present invention relates to compositions and methods for prophylactic and/or therapeutic treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more compounds selected from the group consisting of epicatechin, an epicatechin derivative, catechin, a catechin derivative, nicorandil, and a nicorandil derivative in an amount effective to ameliorate mitochondrial toxicity caused by administration of a chemical, food, or drug.Type: ApplicationFiled: June 5, 2012Publication date: July 4, 2013Inventors: Francisco Villarreal, Alan Maisel, George Schreiner, Guillermo M. Ceballos Reyes, Pam Taub
-
Publication number: 20130165400Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.Type: ApplicationFiled: December 20, 2012Publication date: June 27, 2013Applicant: ALIOS BIOPHARMA, INC.Inventor: Alios BioPharma, Inc.
-
Publication number: 20130157971Abstract: 2?-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 2, 2012Publication date: June 20, 2013Inventors: RAYMOND F. SCHINAZI, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee
-
Patent number: 8466127Abstract: The present invention provides a PEGylated and fatty acid grafted chitosan oligosaccharide comprising a structural unit represented by the following Formula (I) and a structural unit represented by the following Formula (II) and synthesize method, wherein the chitosan oligosaccharide has a molecular weight of less than 200,000 Da, and a degree of deacetylation of 70%-100%, and part of free amino groups of chitosan oligosaccharide chain are replaced by a fatty acid or PEG, where n refers to degree of polymerization of the PEG, and R is an alkyl group having 11-21 carbon atoms. The grafting ratio of fatty acids is 1%-50%, and the grafting ratio of PEG is 0.05%-50%. The present invention also comprise a pharmaceutical composition comprising the PEGylated and fatty acid grafted chitosan oligosaccharide as a carrier, and use of the PEGylated and fatty acid grafted chitosan oligosaccharide in preparation of a pharmaceutical composition.Type: GrantFiled: June 16, 2009Date of Patent: June 18, 2013Assignee: Zhejiang UniversityInventors: Fuqiang Hu, Yongzhong Du, Hong Yuan, Pan Meng
-
Publication number: 20130149283Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.Type: ApplicationFiled: December 28, 2012Publication date: June 13, 2013Applicants: UNIVERSITA DEGLI STUDI DI CAGLIARI, IDENIX PHARMACEUTICALS, INC.Inventors: IDENIX PHARMACEUTICALS, INC., UNIVERSITA DEGLI STUDI DI CAGLIARI
-
Patent number: 8461224Abstract: A method of synthesizing a random copolymer of polyethyleneimine and polyethylene glycol, comprising exposing ethanolamine in a solution to electromagnetic radiation for a sufficient time to polymerize the ethanolamine (OHCH2CH2NH2) and thereby resulting in formation of the randome copolymer comprising polyethyleneimine and poly(ethylene glycol), wherein the polyethyleneimine comprises ethyleneimine (—CH2CH2NH—) unit and the polyethylene glycol comprises ethylene glycol (—CH2CH2O—) unit, and the polyethylenimine of the random copolymer has a substantially linear backbone.Type: GrantFiled: March 4, 2011Date of Patent: June 11, 2013Assignee: National Health Research InstitutesInventors: Shu-Yi Lin, Chung-Shi Yang, Yeu-Kuang Hwu
-
Patent number: 8461123Abstract: Oligonucleotide analogues are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2?-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogues rich in decitabine-deoxyguanosine islets (DpG and GpD) are provided to target the CpG islets in the human genome, especially in the promoter regions of genes susceptible to aberrant hypermethylation. Such analogues can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position. Methods for synthesizing these oligonucleotide analogues and for modulating nucleic acid methylation are provided. Also provided are phosphoramidite building blocks for synthesizing the oligonucleotide analogues, methods for synthesizing, formulating and administering these compounds or compositions to treat conditions, such as cancer and hematological disorders.Type: GrantFiled: February 9, 2010Date of Patent: June 11, 2013Assignee: Astex Pharmaceuticals, Inc.Inventors: Pasit Phiasivongsa, Sanjeev Redkar
-
Patent number: 8461124Abstract: Conformationally locked 2?,4?-carbocylic nucleosides with improved thermal and nuclease stability are disclosed. Oligonucleotides incorporating the locked nucleosides, and methods of treating disease states, are also disclosed.Type: GrantFiled: March 11, 2008Date of Patent: June 11, 2013Inventor: Jyoti Chattopadhyaya
-
Patent number: 8461128Abstract: Many pathogens, including Mycobacterium tuberculosis and Yersinia pestis, rely on an iron acquisition system based on siderophores, secreted iron-chelating compounds with extremely high Fe(III) affinity. The compounds of the invention are inhibitors of domain salicylation enzymes, which catalyze the salicylation of an aroyl carrier protein (ArCP) domain to form a salicyl-ArCP domain thioester intermediate via a two-step reaction. The compounds include the intermediate mimic 5?-O—[N-(salicyl)sulfamoyl]-adenosine (salicyl-AMS) and analogs thereof. These compounds are inhibitors of the salicylate activity of MbtA, YbtE, PchD, and other domain salicylation enzymes involved in the biosynthesis of siderophores. Therefore, these compounds may be used in the treatment of infection caused by microorganisms which rely on siderphore-based iron acquisition systems.Type: GrantFiled: April 14, 2006Date of Patent: June 11, 2013Assignees: Sloan-Kettering Institute for Cancer Research, Cornell Research Foundation, Inc.Inventors: Derek Shieh Tan, Luis E. N. Quadri, Jae-Sang Ryu, Justin Scott Cisar, Julian Alberto Ferreras, Xuequan Lu
-
Patent number: 8450293Abstract: The invention provides analogs cyclic diguanosine monophosphate (c-di-GMP) having different substituents at the guanine C8 position.Type: GrantFiled: August 10, 2011Date of Patent: May 28, 2013Assignee: Rutgers, The State University of New JerseyInventors: Roger A. Jones, Elizabeth Veliath
-
Publication number: 20130122110Abstract: What is disclosed in the invention is a preparation method of a supercritical Cinnamomum subavenium extract, which is made from the material, the dried stem of C. subavenium. The extract is obtained by extracting C. subavenium which is pulverized as particles with supercritical carbon dioxide fluid. The C. subavenium extract or its active ingredient, subamolide A, can be used to inhibit the growth of human urothelial carcinoma cell lines. In addition, the C. subavenium extract (or subamolide A) is able to synergistically inhibit the growth of human urothelial carcinoma cell lines with cisplatin (CDDP) or gemcitabine (Gem). Therefore, the C. subavenium extract (or subamolide A) can be an anticancer drug alone, or forms a pharmaceutical composition with CDDP (or Gem) to treat with cancers in respect of urinary system.Type: ApplicationFiled: March 21, 2012Publication date: May 16, 2013Applicant: KAOHSIUNG MEDICAL UNIVERSITYInventors: JIH-HENG LI, A-MEI HUANG, CHUNG-YI CHEN, PEI-JUNG LIEN, CHIUNG-HUI LIU
-
Patent number: 8440640Abstract: The invention provides methods for, and compositions effective for, treating obesity, inhibiting weight gain, treating diabetes mellitus, inhibiting atherosclerosis and treating related disorders and conditions comprising administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to a patient. The compound capable of inhibiting AC5 may be administered singly or in combination with another agent. In some embodiments, the AC5 inhibiting compound is 9-?-D-arabinofuranosyladenine (AraAde). The compounds may be administered in an amount of about 1 to about 200 mg/kg/day, about 1 to about 100 mg/kg/day, about 10 to about 80 mg/kg/day, about 12 to about 40 mg/kg/day or about 15 to about 25 mg/kg/day. In some embodiments, the compound is administered orally.Type: GrantFiled: November 18, 2009Date of Patent: May 14, 2013Assignee: University of Medicine and Dentistry of New JerseyInventor: Stephen F. Vatner
-
Patent number: 8440638Abstract: Compositions and methods are disclosed which are effective for modulating glucose homeostasis, calcium ion flux and cell death in target cells.Type: GrantFiled: July 20, 2005Date of Patent: May 14, 2013Assignees: Wisconsin Alumni Research Foundation, University of WashingtonInventors: John M. Denu, Andrew M. Scharenberg
-
Publication number: 20130095176Abstract: A controlled release delivery composition comprising: a housing adapted for oral administration; and a plurality of discrete vehicles assembled within the housing, each of the vehicles are not compressed together, each of the vehicles being a bead, a pellet, a tablet, and/or granules compressed into a preselect shape, wherein each of the vehicles comprise a different combination and/or amount of an active agent, an amino acid, a buffer, and a polymer, such that each of the vehicles comprises a different active agent and/or release property from each other, wherein each of the vehicles releases the active agent independently of each other, and wherein each of the vehicles remains independent from each other and intact within the housing prior to oral administration of the delivery composition.Type: ApplicationFiled: September 25, 2012Publication date: April 18, 2013Applicant: Intellipharmaceutics Corp.Inventor: Intellipharmaceutics Corp.
-
Publication number: 20130090299Abstract: The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: October 17, 2012Publication date: April 11, 2013Applicant: Gilead Sciences, Inc.Inventor: Gilead Sciences, Inc.
-
Publication number: 20130078256Abstract: The invention is related to compounds of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.Type: ApplicationFiled: November 20, 2012Publication date: March 28, 2013Applicant: Korea Research Institute of Chemical TechnologyInventor: Korea Research Institute of Chemical Technology
-
Publication number: 20130078217Abstract: The present invention relates to 2?-chloroacetylenyl-substituted nucleoside derivatives of the general formula (I): As well as pharmaceutical compositions comprising such compounds and methods to treat or prevent an HIV infection, HBV infection, HCV infection or abnormal cellular proliferation, comprising administering said compounds or compositions. In addition, the present invention includes processes for the preparation of such compounds, and the related ?-D and ?-L-nucleoside derivatives.Type: ApplicationFiled: September 21, 2012Publication date: March 28, 2013Inventors: Guoqiang Wang, In Jong Kim, Yat Sun Or
-
Patent number: 8404651Abstract: The present invention provides compositions methods for treating susceptible viral infections, especially hepatitis C viral (HCV) infections as well as co infections of HCV with other viruses such as HBV and/or HIV. In one embodiment, the present invention provides compositions having the formula (I) and their use in treating viral infections: or a pharmaceutically acceptable salt, ester, stereoisomer, tautomers, solvate, prodrug, or combination thereof.Type: GrantFiled: October 4, 2010Date of Patent: March 26, 2013Assignee: Spring Bank Pharmaceuticals, Inc.Inventors: Radhakrishnan P. Iyer, Seetharamaiyer Padmanabhan
-
Publication number: 20130071354Abstract: Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.Type: ApplicationFiled: November 16, 2012Publication date: March 21, 2013Applicant: Gilead Sciences, Inc.Inventor: Gilead Sciences, Inc.
-
Patent number: 8399428Abstract: The invention provides a compound of formula (I), wherein R1-R6 and X have any of the values described, as well as pharmaceutical compositions comprising such compounds and therapeutic methods comprising the administration of such compounds.Type: GrantFiled: December 8, 2005Date of Patent: March 19, 2013Assignee: Regents of the University of MinnesotaInventor: Carston R. Wagner
-
Publication number: 20130064789Abstract: The present invention relates to hairy cell leukemia biomarkers and methods of utilizing these biomarkers to diagnose and/or treat hairy cell leukemia.Type: ApplicationFiled: May 10, 2012Publication date: March 14, 2013Inventors: Brunangelo Falini, Raul Rabadan, Enrico Tiacci
-
Publication number: 20130035306Abstract: The present invention provides for the preparation ?-adenine nucleosides by coupling an adenine derivative containing an unprotected exocyclic amino group at the C-6 position and a blocked arabinofuranosyl derivative, in the presence of a base and solvent. The present invention also provides for the stereoselective preparation of 2-deoxy-?-D-adenine nucleosides wherein a blocked 2-deoxy-?-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative. The forgoing aspects of the present invention are utilized in the preparation of a clofarabine composition wherein the ratio of ? to ?-anomer is at least 99:1.Type: ApplicationFiled: July 6, 2012Publication date: February 7, 2013Applicant: Genzyme CorporationInventors: William E. Bauta, Brian D. Burke, Brian E. Schulmeier, William R. Cantrell, JR., Dennis P. Lovett, Jose Puente
-
Patent number: 8361988Abstract: The present invention comprises compounds useful as antiviral or antitumor agents. The compounds comprise nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moeities with quaternary centers at the 3? position. The nucleotide analogues can be used to inhibit cancer or viruses. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses. Thus, the present invention also comprising pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit viruses or tumors and treat, prevent, or inhibit the foregoing diseases.Type: GrantFiled: January 17, 2008Date of Patent: January 29, 2013Assignee: Institut de Recherches Cliniques de MontrealInventor: Yvan Guindon
-
Publication number: 20130022687Abstract: The present invention proposes a cosmetic or pharmaceutical preparation that comprises a mixture of nutritional related co-factors synergistically combined and applied as a topical/transdermal surfactant. Said surfactant formula invokes a precise ordered and sequential synchrony within the treated area initiating the bodies' own natural biological and healing circadia. Said surfactant formula has the ability to regulate an inflammation response and infuse required nutrients for cellular repair at the treated area. The specific ingredients serve as a co-synergist for a clearly defined series of cascading biochemical loops that substantiate the use of each individual ingredient. The concert of regulation of an inflammation response coupled with infused nutritional co-factors and cascading biochemical loops yields a modulation of both chronic and acute inflammation or repair of injured tissue and joints as a result of injury, stress or disease.Type: ApplicationFiled: July 18, 2012Publication date: January 24, 2013Inventors: John James Fitzgerald, JR., Ranya Ludwig Alexander, Anthony Joseph Meduri
-
Publication number: 20130023463Abstract: A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.Type: ApplicationFiled: April 19, 2012Publication date: January 24, 2013Applicant: ABBOTT LABORATORIESInventors: Charles A. Flentge, Hui-Ju Chen, David A. DeGoey, William J. Flosi, David J. Grampovnik, Peggy P. Huang, Dale J. Kempf, Larry L. Klein, Allan C. Krueger, Darold L. Madigan, John T. Randolph, Minghua Sun, Ming C. Yeung, Chen Zhao
-
Patent number: 8349811Abstract: A stable 6-methoxy-2?,3?-dideoxyguanosine comprises 6-30% water content. It is prepared by absorbing water in 6-methoxy-2?,3?-dideoxyguanosine with less than 6% water content at low temperature and certain humidity, or drying 6-methoxy-2?,3?-dideoxyguanosine with more than 30% water content. The stable 6-methoxy-2?,3?-dideoxyguanosine can be used to prepare medicament composition, and be used to manufacture pharmaceutical for fighting hepatitis B virus or HIV.Type: GrantFiled: October 10, 2008Date of Patent: January 8, 2013Assignee: Nanjing Changao Pharmaceutical Science & Technology Co., LimitedInventors: Zhan Li, Haiyan Huang, Cailian Liu, Lixun Jiang
-
Patent number: 8343478Abstract: The present invention relates to the use of Parapoxviruses in combination with other agents for the treatment of viral diseases, and in particular HIV infections and AIDS. The invention also relates to methods for producing medicaments based on combinations of Parapoxviruses and other antiviral agents, and to such medicaments. In particular, the invention relates to the use of Parapoxviruses in combination with agents of the kind used for antiretroviral therapy and highly active antiretroviral therapy (HAART).Type: GrantFiled: January 11, 2007Date of Patent: January 1, 2013Assignee: AiCuris GmbH & Co. KGInventors: Daniela Paulsen, Helga Ruebsamen-Schaeff, Amar Kureishi, Gerhard Hunsmann, Christiane Stahl-Hennig, Andreas Meyerhans, Alexandra Schuetz, Olaf Weber
-
Patent number: 8343937Abstract: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.Type: GrantFiled: September 25, 2006Date of Patent: January 1, 2013Assignees: Idenix Pharmaceuticals, Inc., Universita Degli Studi di CagliariInventors: Jean-Pierre Sommadossi, Paulo LaColla
-
Publication number: 20120321637Abstract: Embodiments are directed to compositions and methods related combination therapy with HERV inhibition.Type: ApplicationFiled: June 18, 2012Publication date: December 20, 2012Applicant: The Board of Regents of the University of Texas SystemInventors: Jianli Dong, Gengming Huang
-
Patent number: 8334364Abstract: [Problems] A derivative of a nucleic acid antimetabolite is demanded which can show a high therapeutic effect at a low dose. [Means For Solving Problems] Disclosed is a high molecular weight derivative of a nucleic acid antimetabolite, which is characterized by comprising a high molecular weight compound comprising a polyethylene glycol moiety and a polymer moiety having a carboxyl group in a side chain and a nucleoside derivative which can act as a nucleic acid antimetabolite, wherein the carboxyl group in the side chain is bound to a hydroxyl group in the nucleoside derivative via an ester bond. Also disclosed is a method for producing the high molecular weight derivative.Type: GrantFiled: November 1, 2007Date of Patent: December 18, 2012Assignee: Nipon Kayaku Kabushiki KaishaInventors: Keiichiro Yamamoto, Kazutoshi Takashio
-
Patent number: 8334270Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.Type: GrantFiled: May 3, 2011Date of Patent: December 18, 2012Assignee: Gilead Pharmasset LLCInventors: Michael Joseph Sofia, Jinfa Du, Peiyuan Wang, Dhanapalan Nagarathnam
-
Publication number: 20120316126Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: ApplicationFiled: August 17, 2012Publication date: December 13, 2012Inventors: Kap-Sun Yeung, Kyle E. Parcella, John A. Bender, Brett R. Beno, Katharine A. Grant-Young, Ying Han, Piyasena Hewawasam, John F. Kadow, Andrew Nickel
-
Patent number: 8329664Abstract: A compound for use in the treatment or prophylaxis of viral infections such, for example as chicken pox or shingles caused by the Varicella Zoster virus, said compound having the general formula (II): wherein X is O, S, NH or CH2, Y is O, S or NH, Z is O, S or CH2, R1 is C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl, and one of R2 and R3 is OH, and the other of R3 and R2 is a neutral, non-polar amino acid moiety, or a pharmaceutically acceptable salt or hydrate thereof. Said neutral, non-polar amino acid moiety R2 or R3 may be (IV): in which R4, R5, R6 and R7 are each independently H or C1-2 alkyl. In preferred embodiments, one of R2 or R3 is valine, leucine, isoleucine or alanine, particularly valine.Type: GrantFiled: May 9, 2007Date of Patent: December 11, 2012Assignees: University College Cardiff Consultants Limited, K.U. Leuven Research and DevelopmentInventors: Christopher McGuigan, Jan Balzarini, Marco Migliore